These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 8772670)
1. International workshop on antithrombotic therapy for acute coronary syndromes. May 9-10, 1996, Como, Italy. Van de Werf F Circulation; 1996 Aug; 94(4):593. PubMed ID: 8772670 [No Abstract] [Full Text] [Related]
2. Antithrombotic therapy in patients with acute coronary syndromes. Levine GN; Ali MN; Schafer AI Arch Intern Med; 2001 Apr; 161(7):937-48. PubMed ID: 11295956 [TBL] [Abstract][Full Text] [Related]
3. [Acute coronary syndromes without ST-elevation -- treatment]. Weber M; Hamm C Dtsch Med Wochenschr; 2003 Feb; 128(6):273-6. PubMed ID: 12571797 [No Abstract] [Full Text] [Related]
4. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied. Goldberg L; Mekel J Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745 [No Abstract] [Full Text] [Related]
5. Glycoprotein IIb/IIIa antagonist and fibrinolytic agents: new therapeutic regimen for acute myocardial infarction. Patel VB; Moliterno DJ J Invasive Cardiol; 2000 Mar; 12 Suppl B():8B-15B. PubMed ID: 10731294 [No Abstract] [Full Text] [Related]
9. [Reperfusion after acute myocardial infarct with fibrinolytic therapy o combination reduced fibrinolytic therapy and a glycoprotein IIb/IIIa inhibitor: the GUSTO V study]. Franzosi MG Ital Heart J Suppl; 2001 Sep; 2(9):1034-6. PubMed ID: 11675828 [No Abstract] [Full Text] [Related]
10. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators N Engl J Med; 1998 May; 338(21):1488-97. PubMed ID: 9599103 [TBL] [Abstract][Full Text] [Related]
11. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease]. Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681 [TBL] [Abstract][Full Text] [Related]
12. [Risk stratification in the acute coronary syndrome. Diabetes--a diagnostic dilemma]. Giannitsis E; Katus HA Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S211-4. PubMed ID: 17109251 [No Abstract] [Full Text] [Related]
13. Facilitation of thrombolysis in acute myocardial infarction. Gambhir DS Indian Heart J; 1999; 51(5):486-8. PubMed ID: 10721636 [No Abstract] [Full Text] [Related]
14. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS). Morrow DA; Sabatine MS; Antman EM; Cannon CP; Braunwald E; Theroux P Am J Cardiol; 2004 Sep; 94(6):774-6. PubMed ID: 15374786 [TBL] [Abstract][Full Text] [Related]
16. [Impact of GP IIb/IIIa antagonists in interventional cardiology]. Scheller B; Hennen B; Böhm M; Nickenig G Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800 [No Abstract] [Full Text] [Related]
17. Logic and logistics: conundrum in reperfusion treatment for acute myocardial infarction. Brener S; Topol EJ Heart; 1999 Oct; 82(4):402-3. PubMed ID: 10490544 [No Abstract] [Full Text] [Related]
18. Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study). Huynh T; Theroux P; Snapinn S; Wan Y; Am Heart J; 2003 Oct; 146(4):668-73. PubMed ID: 14564321 [TBL] [Abstract][Full Text] [Related]
19. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors: in the management of acute coronary syndromes. Bosanquet N; Jönsson B; Fox KA Pharmacoeconomics; 2003; 21(16):1135-52. PubMed ID: 14594436 [TBL] [Abstract][Full Text] [Related]